RBC Capital Initiates KemPharm With Outperform

by Monica Gerson, Benzinga Staff Writer
May 11, 2015 8:32 AM | 11 seconds read | Make a Comment
Loading...
Loading...
RBC Capital initiated coverage on
KemPharm IncKMPH
with a Outperform rating. The target price for KemPharm is set to $18. KemPharm shares rose 5.75 percent to close at $12.05 on Friday.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Posted In: InitiationAnalyst RatingsRBC Capital
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!